Developing new medicines for pancreatic cancer
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
This research is creating new, more effective medicines to fight pancreatic cancer by targeting how cancer cells get their energy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11136257 on NIH RePORTER |
What this research studies
Pancreatic cancer can be very challenging to treat, and we are always looking for better options. This project focuses on a vital energy process within cancer cells called oxidative phosphorylation (OXPHOS), which they rely on to grow and spread. While some existing medicines like metformin have shown a little promise by targeting this pathway, they are not strong enough or selective enough. Our scientists are working to develop new, powerful drugs that specifically block this energy source in pancreatic cancer cells, aiming for more effective and targeted treatment.
Who could benefit from this research
Good fit: Patients with pancreatic cancer who might benefit from new, targeted therapies could be ideal candidates for future clinical trials stemming from this work.
Not a fit: Patients without pancreatic cancer would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, these new medicines could offer a more effective and targeted way to treat pancreatic cancer, potentially improving patient outcomes.
How similar studies have performed: Previous research with a less potent drug, metformin, has shown some increased survival in pancreatic cancer patients, suggesting that targeting this energy pathway can be beneficial.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Neamati, Nouri — University of Michigan at Ann Arbor
- Study coordinator: Neamati, Nouri
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.